ARVINDREM

Members of the Exchange are hereby notified that in terms of Regulation 22(6) of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, Section 21A of the Securities Contract (Regulations) Act, 1956, Rule 21(2) b of Securities Contract (Regulations) Rules, 1957 , it has been decided to delist (withdraw the admission to dealings in) equity shares of the Arvind Remedies Limited w.e.f. August 08, 2018 as per Chapter V of SEBI (Delisting of Equity Shares) Regulations, 2009.

Members of the Exchange are hereby informed that the Exchange on February 28, 2018 has issued public notice in the newspaper for�� proposed compulsory delisting of equity shares of the company, in term of Regulation 22 (3) of SEBI (Delisting of Equity shares) Regulation, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/common/CorporateAnnouncements).

Arvind Remedies Limited has informed the Exchange that the decision to appoint Dr. Timothy and Mr. M Vasudevan as Additional Directors of the Company in view of the investment by M/s. Global Allied pharmaceuticals LLC.However, since the investment did not take place, the appointments were not effected.Further, the Directors information on the company from the company site the names of the above persons as directors, and in view of the above, .

Arvind Remedies Limited has submitted to the Exchange the standalone financial results along with the Limited Review Report for the period ended June 30, 2016.

Arvind Remedies Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 12, 2016, decided to defer all other items, intimated vide Company's letter dated August 02, 2016 to the next meeting.

Dr B Arvind Shah has submitted to the Exchange vide letter dated May 25, 2016 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dr B Arvind Shah has submitted to the Exchange vide letter dated May 13, 2016 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Arvind Remedies Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from April 15, 2016 to April 18, 2016 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on April 18, 2016.

Arvind Remedies Limited has informed the Exchange that the company has obtained further extension upto March 2016 to hold the Annual General Meeting for the financial year ended June 30, 2015. A copy of the approval dated December 23, 2015 received from the Registrar of Companies is enclosed.

Arvind Remedies Limited has informed the Exchange that the Board Meeting held on November 26, 2015 has discussed in detail reasons for the delay, the financial constraints through which the company is passing through, and the restructuring request with the banks through investor by SDR route for which negotiations are going on. Board felt that instead of considering unaudited results for the quarters ended March 31, 2015 and June 30, 2015 to avoid the notice of suspension, since the audit is going on, it is advisable to come out with the audited results for these quarters, along with the unaud

Arvind Remedies Limited has informed the Exchange that Mr. Sudhir Chandra, Director has resigned from the Company w.e.f. November 5, 2015. The above were considered by the Director in its meeting and same was approved.

Arvind Remedies Limited has informed the Exchange that it has been decided by the Board of Directors in their meeting that the financial year ending of 2014-15 will be June 30, 2015 and that the company will have the audited results for the 15 months. The company has requested the Registrar of Companies for extension of time to hold the Annual General Meeting by 3 months, i.e till December 2015.The Board will consider the audited financial results for the quarter ended March 31, 2015 and the quarter and year ended June 30, 2015 in one meeting, once the audit is completed. Company had sought ea

Arvind Remedies Limited has informed the Exchange that with reference to Company's letter dated August 1, 2015 requesting time for submitting financial results for the quarter and year ended March 31, 2015 and June 30, 2015 as per Clause 41 of the Listing requirements.Company have now to inform the Exchange that in view of the delay in conducting the Annual General Meeting before September 30, 2015 as per the requirements, as decided in the Board Meeting the company approached office of Registrar of Companies seeking extension of time by 3 months for holding the AGM and the same has been appro

Arvind Remedies Limited has informed the Exchange that due to administrative reasonsthe Corporate office of the company has been shifted to the factory premises at 38, 39 & 40 SIDCO Industrial Estate, Kakalur, Thiruvellore District, Tamilnadu.

Arvind Remedies Limited has informed the Exchange that in the Board Meeting held on July 11, 2015, the following decisions were taken.(1). Board approved the investment proposal presented by M/s. Global Allied Pharmaceuticals LLc, including product development. It was decided to enter into agreement stating in detail the amount to be invested and the terms and conditions and the same be placed for approval of the shareholders.(2). Considering the proposed investment, it was decided to increase the authorised share capital of the company accordingly.(3). It was decided to appoint Dr. Timothy Al

Arvind Remedies Limited has informed the Exchange that Mr. Selven Daniel CFO, has resigned from the services. The Company has appointed Mr. G. Raghavn as Chief Financial Officer of the Company and he joined the Company.

Arvind Remedies Limited has informed the Exchange regarding outcome of meeting of the Board of Directors of the Company held on May 28, 2015.

Arvind Remedies Limited has informed the Exchange regarding Code of Practices and Procedures for Fair Disclosure of Unpublislied Price Sensitive Information for Board Members and Senior Management Personnel.

Arvind Remedies Limited has informed the Exchange that the trading window of the shares of the company will remain closed in terms of the Code of Conduct to regulate monitor and report trading by insiders formulated pursuant to SEBI Insider Trading Regulations 2015 from May 22, 2015 to May 31,2015 (both days inclusive).

Arvind Remedies Limited has informed the Exchange that with reference to Company's earlier communications informing about strike in Unit No. 1 at Kakkalur, Thiruvallur, Tamil Nadu. Company have now inform the Exchange that since the conciliation efforts have failed, the matter will be continued at the Labour Court. In view of the above position, the strike by the workers stand discontinued.

Arvind Remedies Limited has informed the Exchange that Mr. V R Mehta, Director has resigned from the Company with effect from March 21, 2015. Mr. Madhav Yadav has been appointed as independent director of the Company.

Price movement : Significant price movement has been observed in Arvind Remedies Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Arvind Remedies Limited has vide its letter inter-alia stated, "The Company has been so far complying with all the listing requirements including furnishing information as per Clause 36 that were having bearing on the operations/ performance of the company. As regards the recent price increase, i

Arvind Remedies Limited has submitted to the exchange the standalone financial results for the period ended 31-Dec-2014.

Arvind Remedies Limited has informed the Exchange that the Board of Directors at its meeting held on February 27, 2015 has discussed on the status of strike by workers, the conciliation efforts, and the decision pending at Court. It was informed that due to strike and resultant improper humidity & environment conditions, damage has been caused to the goods in process and thereby there is loss in the current quarter. Board discussed on the debt restructuring proposal which has been taken up in view of the liquidity problem. It was felt that restructuring will be beneficial to the Company, and d

Arvind Remedies Limited has informed the Exchange that in the meeting of Board of Director held on February 11, 2015, the following decisions were taken . 1. Due to issue of further equity shares by Coronet Labs P Ltd, (CLPL) the subsidiary Company, the shareholding of the Company in CLPL reduced substantially and CLPL ceased to be subsidiary. It was decided that this information be given by way of note below the financial results for the quarter ended December 31, 2014. 2. It was decided that in the next Board Meeting convened on February 27, 2015, the Corporate Restructuring proposal with

Arvind Remedies Limited has informed the Exchange that Mr. Ankur Agarwal, Executive Director has resigned from the Company and the same has been approved by the Board.

Arvind Remedies Limited has informed the Exchange that the strike in the unit 1 is continued as on date inspite of best efforts of conciliations by the management. The exact production loss and other losses could be worked out once the situation is normal.

The Exchange has sought clarification from Arvind Remedies Limited with respect to strike by the workers of the Company in Unit No. 1 at Kakkalur since few days raising their demands and that the same has affected production. In this regard, the Exchange has advised the Company to provide clarification/confirmation with respect to the following: (a) The impact of the strike/lock out in some quantifiable terms like loss of production, loss of man-days, etc. The response from the Company is awaited.

Arvind Remedies Limited has informed the Exchange that there has been strike by the workers of the Company in Unit No. 1 at Kakkalur since few days raising their demands and the same has affected the production. The Management has initiated conciliation efforts and hope to bring back normalcy at the earliest.

Arvind Remedies Limited has submitted to the Exchange, vide letter dated November 26, 2014 copies of Disclosures under Regulation 13 of the (Prohibition of Insider Trading) Regulations, 1992.

Aryaman Commerce Private Limited has submitted to the Exchange vide letter dated November 22, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Marina Dealcom Private Limited has submitted to the Exchange vide letter dated November 21, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Juniper Vinimay Private Limited has submitted to the Exchange vide letter dated November 21, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Arvind Remedies Limited has submitted to the Exchange, vide letter dated November 25, 2014, a copy of disclosure under Regulation 13(4) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Arvind Remedies Limited has submitted to the Exchange a copy of disclosure under SEBI (Prohibition of Insider Trading) Regulations, 1992.

Arvind Remedies Limited has informed the Exchange regarding a press release vide their letter dated November 14, 2014 , titled "Arvind Remedies Ltd Q2FY15 net sales grows by 34% at Rs 293 crore Registers Rs 132 crore PAT"

Arvind Remedies Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2014.

Arvind Remedies Limited has informed the Exchange that Mr. R Rajamohan,Director has resigned from the company with effect from November 5, 2014.This was considered in the Board meeting of the Company held on November 13, 2014 and approved.

Arvind Remedies Limited has informed the Exchange that Mr.S. Balakrishnan, Finance Controller of the Company,has resigned from the services. The company has appointed Mr.Selvan Daniel as Chief Financial Officer and he joined the company from October 13, 2014.

Arvind Remedies Limited has submitted to the Exchange a copy of Proceedings on Annual General Meeting of the Company held on September 29, 2014 along with Scrutinizer's Report.

Arvind Remedies Limited has submitted to the Exchange the outcome of the Annual general Meeting of the Company held on September 29, 2014. The shareholders of the Company at the Annual General Meeting have passed all the resolutions with requisite majority.

Arvind Remedies Limited has submitted to the Exchange a copy of disclosure under Regulation 13(4) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Arvind Remedies Limited has informed the Exchange that the Company has fixed Book Closure from September 26, 2014 to September 29, 2014 (both days inclusive) for the purpose of Annual General Meeting scheduled to be held on September 29, 2014 and for payment of dividend.

Arvind Remedies Limited has informed the Exchange that the Board of Directors held on August 09, 2014, following decisions were taken (1)The status of demerger petition filed in High Court, Chennai was discussed. Board felt that considering the changed scenario and for the reasons external to the company, it is advisable not to pursue with the scheme. Accordingly it was decided to withdraw the petition from the High Court. (2).That the shareholders approval for the borrowing powers pursuant to the Companies Act 2013 be taken by e-voting before September 11, 2014.

Arvind Remedies Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2014.

Arvind Remedies Limited has submitted to the Exchange vide letter dated June 10, 2014 a copy of Disclosure under Regulation 13(4) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Arvind Remedies Limited has informed the Exchange, vide letter dated June 11, 2014 regarding "MoU with Adesh University to launch new drugs - Press release".

Arvind Remedies Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 29, 2014 has recommended a dividend of Re.0.80 per equity share of Rs.10 each, subject to the approval of the shareholders in the Annual General Meeting.

Arvind Remedies Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2014.

Arvind Remedies Limited has informed the Exchange vide letter dated May 27, 2014 regarding "MoU with SRM University to launch new drugs for Diabetes and Coronary heart disease- Press release".